Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Janice M. Mehnert et al.|Journal of Thoracic Oncology|2019Cited by 437
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Huafei Li et al.|Lung Cancer|2024Cited by 66
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry studyLauren Brown, Benjamin Y. Kong, Malinda Itchins et al.|Frontiers in Oncology|2024Cited by 6
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 TrialAlexander Drilon, Byoung Chul Cho, Ki Hyeong Lee et al.|Journal of Thoracic Oncology|2024Cited by 0